Adult T-Cell Leukemia/Lymphoma: Relapsed/Refractory

Adult T-Cell Leukemia/Lymphoma

Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Similar to the first-line setting, standard treatment for relapsed/refractory ATLL has not been established. Many chemotherapy regimens used to treat other T-cell lymphomas following a relapse are also being used to treat ALL, including the following:

  • DHAP (dexamethasone, cytarabine, and cisplatin)
  • ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)
  • GDP (gemcitabine, dexamethasone, and cisplatin)
  • ICE (ifosfamide, carboplatin, and etoposide)
  • Pralatrexate (Folotyn)
  • Belinostat (Beleodaq).

Learn More

To learn more about ATLL, download the Adult T-Cell Leukemia/Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.

YouTube video

Additional Resources

To learn more about ATLL, download the Adult T-Cell Leukemia/Lymphoma Fact Sheet.

Events

Lymphoma Talk: Los Angeles

Westdrift Manhattan Beach 1400 Parkview Avenue, Manhattan Beach, California

Lymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides […]